These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20430717)

  • 1. The KPC type beta-lactamases: new enzymes that confer resistance to carbapenems in Gram-negative bacilli.
    Sacha P; Ostas A; Jaworowska J; Wieczorek P; Ojdana D; Ratajczak J; Tryniszewska E
    Folia Histochem Cytobiol; 2009; 47(4):537-43. PubMed ID: 20430717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gram-negative bacteriae with resistance to carbapenems].
    Nordmann P
    Med Sci (Paris); 2010 Nov; 26(11):950-9. PubMed ID: 21106177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens.
    Pfeifer Y; Cullik A; Witte W
    Int J Med Microbiol; 2010 Aug; 300(6):371-9. PubMed ID: 20537585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenemases: molecular diversity and clinical consequences.
    Poirel L; Pitout JD; Nordmann P
    Future Microbiol; 2007 Oct; 2(5):501-12. PubMed ID: 17927473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status report on carbapenemases: challenges and prospects.
    Patel G; Bonomo RA
    Expert Rev Anti Infect Ther; 2011 May; 9(5):555-70. PubMed ID: 21609267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns.
    Rapp RP; Urban C
    Pharmacotherapy; 2012 May; 32(5):399-407. PubMed ID: 22488420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology of infections caused by multiresistant gram-negatives: ESBLs, MBLs, panresistant strains.
    Rossolini GM; Mantengoli E; Docquier JD; Musmanno RA; Coratza G
    New Microbiol; 2007 Jul; 30(3):332-9. PubMed ID: 17802921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
    Rossolini GM; Luzzaro F; Migliavacca R; Mugnaioli C; Pini B; De Luca F; Perilli M; Pollini S; Spalla M; Amicosante G; Toniolo A; Pagani L
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4023-9. PubMed ID: 18809945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbapenem-hydrolyzing gram-negative bacteria: current options for treatment and review of drugs in development.
    Abandeh FI; Drew ME; Sopirala MM
    Recent Pat Antiinfect Drug Discov; 2012 Apr; 7(1):19-27. PubMed ID: 22211694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria.
    Nordmann P; Cuzon G; Naas T
    Lancet Infect Dis; 2009 Apr; 9(4):228-36. PubMed ID: 19324295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of carbapenemases in Latin America.
    Maya JJ; Ruiz SJ; Blanco VM; Gotuzzo E; Guzman-Blanco M; Labarca J; Salles M; Quinn JP; Villegas MV
    Expert Rev Anti Infect Ther; 2013 Jul; 11(7):657-67. PubMed ID: 23879607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [KPC carbapenemases: what is at stake in clinical microbiology?].
    Cuzon G; Naas T; Nordmann P
    Pathol Biol (Paris); 2010 Feb; 58(1):39-45. PubMed ID: 19854586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
    Guervil DJ; Chau T
    Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation].
    Martínez-Martínez L; Calvo J
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():25-31. PubMed ID: 21130927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.
    Livermore DM; Woodford N
    Trends Microbiol; 2006 Sep; 14(9):413-20. PubMed ID: 16876996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of carbapenemases on antimicrobial development and therapy.
    Livermore DM
    Curr Opin Investig Drugs; 2002 Feb; 3(2):218-24. PubMed ID: 12020049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.